Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review
- PMID: 37332984
- PMCID: PMC10272733
- DOI: 10.3389/fneur.2023.1207617
Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review
Abstract
Multiple sclerosis (MS) primarily affects adult females. However, in the last decades, rising incidence and prevalence have been observed for demographic extremes, such as pediatric-onset MS (POMS; occurring before 18 years of age) and late-onset MS (corresponding to an onset above 50 years). These categories show peculiar clinical-pathogenetic characteristics, aging processes and disease courses, therapeutic options, and unmet needs. Nonetheless, several open questions are still pending. POMS patients display an important contribution of multiple genetic and environmental factors such as EBV, while in LOMS, hormonal changes and pollution may represent disease triggers. In both categories, immunosenescence emerges as a pathogenic driver of the disease, particularly for LOMS. In both populations, patient and caregiver engagement are essential from the diagnosis communication to early treatment of disease-modifying therapy (DMTs), which in the elderly population appears more complex and less proven in terms of efficacy and safety. Digital technologies (e.g., exergames and e-training) have recently emerged with promising results, particularly in treating and following motor and cognitive deficits. However, this offer seems more feasible for POMS, being LOMS less familiar with digital technology. In this narrative review, we discuss how the aging process influences the pathogenesis, disease course, and therapeutic options of both POMS and LOMS. Finally, we evaluate the impact of new digital communication tools, which greatly interest the current and future management of POMS and LOMS patients.
Keywords: aging; engagement; immunosenescence; late-onset; multiple sclerosis; pediatric-onset; risk factors; unmet need.
Copyright �� 2023 Capasso, Virgilio, Covelli, Giovannini, Foschi, Montini, Nasello, Nilo, Prestipino, Schirò, Sperandei, Clerico and Lanzillo.
Conflict of interest statement
RL and MC received financial compensation for attendance to expert meetings as part of an educational programme by Merck Serono S.p.A., Rome, Italy, an affiliate of Merck. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis.Mult Scler Relat Disord. 2021 May;50:102816. doi: 10.1016/j.msard.2021.102816. Epub 2021 Feb 4. Mult Scler Relat Disord. 2021. PMID: 33571792 Review.
-
Late-Onset MS: Disease Course and Safety-Efficacy of DMTS.Front Neurol. 2022 Mar 10;13:829331. doi: 10.3389/fneur.2022.829331. eCollection 2022. Front Neurol. 2022. PMID: 35356454 Free PMC article. Review.
-
As time goes by: Treatment challenges in elderly people with multiple sclerosis.J Neuroimmunol. 2024 Jun 15;391:578368. doi: 10.1016/j.jneuroim.2024.578368. Epub 2024 May 14. J Neuroimmunol. 2024. PMID: 38761652 Review.
-
Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis.J Clin Med. 2020 May 2;9(5):1326. doi: 10.3390/jcm9051326. J Clin Med. 2020. PMID: 32370288 Free PMC article.
-
Characterization of a late-onset multiple sclerosis Portuguese cohort.Mult Scler Relat Disord. 2023 Feb;70:104506. doi: 10.1016/j.msard.2023.104506. Epub 2023 Jan 7. Mult Scler Relat Disord. 2023. PMID: 36638770
Cited by
-
Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis.Lancet Reg Health Eur. 2024 Aug 22;44:100978. doi: 10.1016/j.lanepe.2024.100978. eCollection 2024 Sep. Lancet Reg Health Eur. 2024. PMID: 39444702 Free PMC article. Review.
-
Review of evidence linking exposure to environmental stressors and associated alterations in the dynamics of immunosenescence (ISC) with the global increase in multiple sclerosis (MS).Immun Ageing. 2024 Oct 22;21(1):73. doi: 10.1186/s12979-024-00473-w. Immun Ageing. 2024. PMID: 39438909 Free PMC article. Review.
-
Associations between Mediterranean Diet Adherence, Quality of Life, and Mental Health in Patients with Multiple Sclerosis: A Cross-Sectional Study.J Pers Med. 2024 Feb 11;14(2):199. doi: 10.3390/jpm14020199. J Pers Med. 2024. PMID: 38392632 Free PMC article.
-
Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis.Brain Commun. 2024 Jan 29;6(1):fcae021. doi: 10.1093/braincomms/fcae021. eCollection 2024. Brain Commun. 2024. PMID: 38385000 Free PMC article.
-
From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment.Biomedicines. 2023 Nov 16;11(11):3069. doi: 10.3390/biomedicines11113069. Biomedicines. 2023. PMID: 38002068 Free PMC article. Review.
References
-
- Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M, Blaschek A, Valis M, Aaen G, et al. . Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis. Front Neurol. (2020) 11:606418. doi: 10.3389/fneur.2020.606418, PMID: - DOI - PMC - PubMed